MediciNova 8-K 2005
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 30, 2005
(Exact name of registrant as specified in its charter)
4350 La Jolla Village Drive, Suite 950
San Diego, CA 92122
(Address of principal executive offices) (Zip Code)
Registrants telephone number, including area code: (858) 373-1500
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
On September 30, 2005, the Board of Directors of the Registrant and Takashi Kiyoizumi, MD, Ph.D, President and Chief Executive Officer and Chief Financial Officer and a Director of the Registrant, agreed that Dr. Kiyoizumi would resign from all his positions with the Registrant, effective immediately. The Registrant intends to honor the terms of Dr. Kiyoizumis employment contract with the Registrant, which provides for continuation of Dr. Kiyoizumis salary, bonus and benefits for a period of twelve months following termination of his employment with the Registrant without cause. Yuichi Iwaki, MD, Ph.D, Executive Chairman of the Registrant, will serve as acting Chief Executive Officer and acting Chief Financial Officer. Also on September 30, 2005, Brian Anderson, Chief Business Officer of the Registrant, left the Registrant.
Attached as Exhibit 99.1 hereto and incorporated herein by reference in its entirety is the press release issued by the Company on September 30, 2005.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: September 30, 2005.